AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17135812
Drug: Resource Use
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resource Use Inventory (RUI) administered at home or in clinic
Trial: 17135812
Drug: Resource Use
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resource Use Inventory (RUI) administered with help of study partners
Trial: 10674594
Drug: Transdermal 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐estradiol (E2) 50 microg/day for 14 weeks
Trial: 10674594
Drug: Identical transdermal
RxNorm normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical transdermal placebo patches
Trial: 1407642
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 gm single preoperative dose)
Trial: 1407642
Drug: Cefazolin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (3 gm daily for one week post-surgery)
Trial: 31009765
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered oxytocin (OT)
Trial: 26775631
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin (100 mg dose)
Trial: 25139487
Drug: Topical erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical erythromycin (two applications of 800 mg)
Trial: 25139487
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (250 mg)
Trial: 25139487
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (1000 mg)
Trial: 17993095
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol infused at a rate of 3 to 4 mg kg(‐1) h(‐1) (Group A)
Trial: 16341745
Drug: Complex pharmaceutical
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex pharmaceutical care intervention by pharmacists
Trial: 8925656
Drug: Hydroxyurea (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (15 mg/kg/day titrated to maximum tolerated dose up to 35 mg/kg/day)
Trial: 6199481
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) IV daily for 10 days
Trial: 29508470
Drug: nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nicotine replacement therapy (NRT)
Trial: 27266867
Drug: Fufangdanshen (FFDS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufangdanshen (FFDS) tablets, 3 tablets three times per day for 24 weeks
Trial: 27266867
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 tablets three times per day for 24 weeks
Trial: 26462765
Drug: Mucinex 1200
RxNorm normalized name: Mucinex 1200 MG Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucinex 1200 mg (2 x 600 mg extended release tablets)
Trial: 11518588
Drug: Acoustic analysis
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic analysis of voice parameters (jitter, shimmer, Fo tremor, HNR) during treatment
Trial: 9623511
Drug: Thalidomide treatment
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide treatment for 1 or 2 months
Trial: 9623511
Drug: Thalidomide treatment
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide treatment for 1 month
Trial: 9623511
Drug: Thalidomide treatment
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide treatment for 2 months
Trial: 3335825
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of estrogen-progestin preparation
Trial: 29757661
Drug: Levothyroxine sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine sodium administered daily either as the whole dose q 24 hr or as half the dose q 12 hr, starting at 0.1 mg/10 lb (0.022 mg/kg) for approximately 6 months
Trial: 17319111
Drug: Norepinephrine, Clonidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine, Clonidine, L-NMMA (nonselective alpha-adrenoceptor agonists)
Trial: 17319111
Drug: Methoxamine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxamine (selective alpha1-adrenoceptor agonist)
Trial: 7707598
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (controls)
Trial: 2710801
Drug: Onion consumption
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onion consumption (70 g raw onion daily for 7 days)
Trial: 2710801
Drug: Ginger consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger consumption (5 g raw ginger daily for 7 days)
Trial: 31600109
Drug: Autologous PRP
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous PRP gel
Trial: 27617680
Drug: Webcam Lidcombe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Webcam Lidcombe Program treatment
Trial: 27617680
Drug: Standard Lidcombe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Lidcombe Program treatment
Trial: 22405570
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine followed by erlotinib at disease progression (arm A)
Trial: 19885979
Drug: Selection for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selection for targeted treatment effect
Trial: 19885979
Drug: Prognostic targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prognostic targeting for targeted treatment effect
Trial: 17189085
Drug: Experimental formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formula containing 2 x 10(7) colony-forming units of Bifidobacterium longum BL999 and 4 g/L of prebiotic mixture (90% galacto-oligosaccharides and 10% fructo-oligosaccharides)
Trial: 9892571
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg intramuscular piroxicam
Trial: 9892571
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg intramuscular diclofenac sodium
Trial: 2126198
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined oestrogen/progestogen therapy (2 mg of 17 beta‐oestradiol combined with 1 mg of norethisterone acetate orally each day continuously for 5 years)
Trial: 2126198
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined oestrogen/progestogen therapy
Trial: 389150
Drug: Guanidine hydrochloride
RxNorm normalized name: Guanidine Hydrochloride
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guanidine hydrochloride (20 to 35 mg/kg per day perorally)
Trial: 30412909
Drug: Indigenous Counselling
RxNorm normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention including educational resource packages, live interactive webinars, treatment manuals, patient resources, carbon monoxide (CO) meters, and oral Nicotine Replacement Therapy (NRT).
Trial: 24994768
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance exercise (PRE) program, 12 weeks, twice a week, using machines with free weights at 50% and 70% of one-repetition maximum (1RM).
Trial: 24994768
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) remained on a waiting list for physical therapy.
Trial: 19118954
Drug: 10mg oxycodone
RxNorm normalized name: oxycodone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg oxycodone (OXY)/487 mg acetaminophen (ACET)
Trial: 19118954
Drug: 20mg oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg oxycodone (OXY)/975 mg acetaminophen (ACET)
Trial: 19118954
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg hydrocodone (HYD)/487 mg acetaminophen (ACET)
Trial: 19118954
Drug: 30mg hydrocodone
RxNorm normalized name: hydrocodone bitartrate 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg hydrocodone (HYD)/975 mg acetaminophen (ACET)
Trial: 19118954
Drug: 975 mg
RxNorm normalized name: aspirin 975 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 975 mg acetaminophen (ACET)
Trial: 11374113
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage monophasic oral contraceptives (OC) - days 5-8
Trial: 11374113
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage monophasic oral contraceptives (OC) - days 19-21
Trial: 11374113
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage monophasic oral contraceptives (OC) - run 5 days 5-8
Trial: 11374113
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage monophasic oral contraceptives (OC) - run 5 days 19-21
Trial: 9589244
Drug: high‐mixture 75/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high‐mixture 75/25 insulin lispro/NPL insulin
Trial: 9589244
Drug: mid‐mixture 50/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mid‐mixture 50/50 insulin lispro/NPL insulin
Trial: 9589244
Drug: low‐mixture 25/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low‐mixture 25/75 insulin lispro/NPL insulin
Trial: 9589244
Drug: insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: insulin lispro
Trial: 15278585
Drug: Atropinized group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropinized group (0.015 mg.kg(‐1) i.m.)
Trial: 3924984
Drug: Cromolyn Sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn Sodium (CS) 20 mg inhaled four times daily
Trial: 3924984
Drug: Long-acting Theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting Theophylline (LAT) administered twice daily to achieve mean blood levels of 14.0 +/- 1.6 SEM micrograms per milliliters
Trial: 30272170
Drug: Dulaglutide (Trulicity®)
RxNorm normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide (Trulicity®) 1.5 mg
Trial: 29160002
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic (TA) cream
Trial: 26775671
Drug: 5‐aminolevulinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT), 4 sessions at 2‐week intervals
Trial: 26775671
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate (0.05%), daily for 8 weeks
Trial: 26775671
Drug: 5‐aminolevulinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT)
Trial: 15048062
Drug: Rescue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy combining amsacrine 120 mg/m(2)/day (days 1-3), cytarabine 1 g/m(2)/12 h (days 1-5), and etoposide 100 mg/m(2)/day (days 1-5)
Trial: 15048062
Drug: Rescue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy combining amsacrine, cytarabine, and etoposide
Trial: 8556567
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) containing BKC
Trial: 2169077
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (subcutaneous injection once daily)
Trial: 40584
Drug: Oral cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cimetidine (1 g daily for 1 week)
Trial: 40584
Drug: H1 receptor
RxNorm normalized name: Histamine H1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 receptor antagonist chlorpheniramine
Trial: 31587493
Drug: PDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT with active formulation cream (licochalcone A, L-carnitine, and decanediol)
Trial: 31587493
Drug: PDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT with active formulation cream
Trial: 31587493
Drug: PDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT with vehicle cream
Trial: 21696114
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene indices (VPI and GBI)
Trial: 19432036
Drug: Intermittent balneotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent balneotherapy in a sulfur pool heated to 35-36 degrees C, twice weekly for 6 weeks
Trial: 11401935
Drug: Deferoxamine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine (500 mg intra-arterially over 1 hour)
Trial: 8010314
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone and metoclopramide
Trial: 27836586
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for presumed adverse events (administration of antibiotics, misoprostol or surgical evacuation).
Trial: 27836586
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for presumed adverse events in the control group.
Trial: 11403977
Drug: Buserelin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (low dose gonadotropin releasing hormone agonist)
Trial: 8214647
Drug: Amrinone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (1.5 mg/kg)
Trial: 8214647
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amrinone and epinephrine
Trial: 28669606
Drug: 150 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 minutes per week of aerobic exercise (low-dose)
Trial: 28669606
Drug: 300 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 minutes per week of aerobic exercise (high-dose)
Trial: 27391774
Drug: Intradialytic exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic exercise programme (30 min continuous cycling thrice weekly during dialysis)
Trial: 24215215
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cefazolin (CEZ)
Trial: 22334806
Drug: Unattended polysomnography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unattended polysomnography at baseline and auto-titrating CPAP therapy for up to one year
Trial: 18357500
Drug: Stanger bath
RxNorm normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stanger bath therapy and exercise program (n = 30)
Trial: 16522454
Drug: FSC 100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSC 100/50 microg twice daily
Trial: 16522454
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 250 microg twice daily
Trial: 11075843
Drug: Rizatriptan wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan wafer 10 mg
Trial: 8792758
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) with high dosage and bilateral electrode placement
Trial: 8792758
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) with low dosage and right unilateral electrode placement
Trial: 31590426
Drug: Cyano-B12 (CN-B12)
RxNorm normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyano-B12 (CN-B12) capsules (2 × 2.8 µg/day)
Trial: 31590426
Drug: Cyano-B12 (CN-B12)
RxNorm normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyano-B12 (CN-B12) capsules
Trial: 29911775
Drug: Silver nanoparticle
RxNorm normalized name: Silver nanoparticle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver nanoparticle gel with 2.5% benzoyl peroxide
Trial: 29911775
Drug: Clindamycin gel
RxNorm normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin gel with 2.5% benzoyl peroxide
Trial: 17580443
Drug: Medication (Amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Amitriptyline 50 mg/d initially, increased to 200 mg/d)
Trial: 9934405
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (40 mcg) inhaled before the methacholine test
Trial: 31965573
Drug: Hypovolaemic phlebotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypovolaemic phlebotomy (7-10 ml per kg whole blood removed, without intravenous fluid replacement)
Trial: 28060581
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n = 20)
Trial: 17216727
Drug: Saccharine (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharine (22.5 mg)
Trial: 17216727
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of saccharine (22.5 mg) and cyclamate (150 mg)
Trial: 14584388
Drug: Pranlukast therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast therapy for 4 weeks, continued for Group I for an additional two years.
Trial: 14584388
Drug: Pranlukast therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast therapy continued for Group II for one more year after showing a 5% or greater increase in PEFR after one year.
Trial: 14584388
Drug: Medication was
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication was suspended for Group III after failing to show improvement in PEFR after one year.
Trial: 8879928
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing with serial dilutions of isoeugenol
Trial: 8879928
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing with isoeugenol
Trial: 11073141
Drug: Cefminox 2
RxNorm normalized name: cefminox
DrugBank: Cefminox (DB09062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefminox 2 g/12 h
Trial: 11073141
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg/8 h and Gentamicin 80 mg/8 h (M+G)
Trial: 1529929
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (short-term) with or without long-acting nitrates (chronic)
Trial: 15762903
Drug: Guideline-based care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based care suggestions delivered to physicians and pharmacists when writing orders or filling prescriptions using computer workstations.
Trial: 12090977
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anastrozole plus tamoxifen
Trial: 2011161
Drug: Mifepristone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (12.5 or 25 mg per kilogram of body weight)
Trial: 6119183
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metipranolol and isosorbide‐5‐mononitrate